{"doi":"10.1002/9781119633884.index","title":"Index","abstract":"1043 infectious factors 177 infectious pathogens 1044 malignancy 1043 medical nonadherence 1043 multidisciplinary factors 177 organ failure 1043 patient factors 176-177 severe obesity 1044 special considerations 177-179 absolute neutrophil count (ANC) 139 acid-fast bacilli (AFB) 1134 activated B cells 154 activated clotting time (ACT) 342, 365, 602-603, 1177, 1188, 1195, 1206 activated partial thromboplastin time (aPTT) 602, 603, 1206 activation-induced cell death (AICD) 157 acute cellular rejection (ACR) 102, 131, 155, 156, 449-450, 459, 462, 1208, 1250, 1268.See also antibody-mediated rejection (AMR) antithymocyte globulin 455-456 causes readmission 532 corticosteroids 455 grade A2 cellular rejection 1272f grade A3 cellular rejection 1272f hemodynamic compromise 458 histology of 1270-1272 ISHLT standardized biopsy grading system for 451, 452t lead to LV dysfunction 537 pathological A-grade classification of 1271t pathological B-grade classification 1272t pathologic grading of 1200t acute cellular rejection 1200-1201 acute coronary syndrome (ACS) 561, 581 acute decompensated heart failure (ADHF) 214, 227, 966, 559, 561-562.See also heart failure (HF) cardiogenic shock 217 cardiorenal syndrome 217 causes and precipitating factors 214 classification 214 diagnosis and evaluation 218-219 differential diagnosis 219-220 durable mechanical circulatory support 226-227 epidemiology 214-215 hypertension 216 hypertensive or normotensive ADHF patient management 221-222 hypotensive ADHF patient management 222-226 presentation 215, 216 prognostic factors 215, 216t pulmonary edema 216-217 right-sided heart failure 217 Stevenson's four-quadrants presentation and treatments 215f transitioning acute HF therapies to chronic HF GDMT 226 treatment 220-221 Index 1405 acute heart failure (AHF) 186, 190, 599 in children 768 DOSE trial 191 inotropes in 222 starling curves for 605f therapies transitioning to chronic HF GDMT 226 VA ECMO for 598 acute humoral and cellular rejection 1391-1392 acute idiopathic interstitial pneumonias 1063 acute interstitial pneumonia (AIP) 1063 acute kidney injury (AKI) 188, 202, 409, 532, 566, 665f, 1178, 1209, 1321 in CS 569 following LVAD surgery 664 after heart transplant 411 in LVAD candidate 673 and renal function 967, 968 acute lung failure patient and temporary mechanical support 1070 absolute contraindications 1072t candidacy and timing of lung transplantation 1074-1075 complications associated with ECMO support 1077-1078 contraindications for patient selection 1075-1076 criteria for ECMO initiation 1073-1074 criteria for lung transplantation 1072-1073, 1075t ECMO as bridge to lung transplant 1071-1073 ECMO cannulation strategies 1077 history of ECMO 1070-1071 history of lung transplant 1070 landmark repair 1071f lung transplantation surgery 1076-1077 optimal timing for transplant 1075 outcomes 1078-1079 patient selection 1074 physical therapy for patients on VV ECMO 1076 relative contraindications 1073t role of ECMO in BTT 1074 acute lung transplant rejection 1208, 1269 allograft sampling techniques 1270 AMR with neutrophilic capillaritis 1273f C4d deposition in alveolar capillaries 1273f clinical presentation and assessment 1269-1270 emerging diagnostic modalities 1274-1275 epidemiology 1269 grade 1R bronchiolar inflammation 1273f histological findings 1270-1274 histopathological changes 1274t morphological changes in transbronchial samples 1271t risk factors 1269 surveillance bronchoscopy and biopsy 1275 treatment strategies 1275-1276 acute MCS in children 767-768 acute myocardial infarction (AMI) 627 acute myocardial infarction/cardiogenic shock (AMI/CS) 559, 561-562 acute normovolemic hemodilution 348 acute renal failure (ARF) 217 acute respiratory distress syndrome (ARDS)","journal":null,"year":2023,"id":411449,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9208,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":681854,"name":"Scott Silvestry","orcid":"0000-0003-1847-5218","position":1,"is_corresponding":false},{"id":107525,"name":"Mani A. Daneshmand","orcid":"0000-0002-0191-9911","position":2,"is_corresponding":false},{"id":681855,"name":"Daniel J. Goldstein","orcid":"0000-0002-6519-4809","position":3,"is_corresponding":false},{"id":435509,"name":"Yaron D. Barac","orcid":"0000-0002-4688-2358","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T01:21:42.971455Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}